Carl Weissman

Carl Weissman General Information

Biography

Mr. Carl Weissman served as Acting Chief Executive Officer at OSS Healthcare. He is a 19 year veteran of the biotechnology industry, working both in venture capital and in companies. Prior to this, Carl was the CEO of Accelerator Corporation, and biotechnology investment and management company that he helped found with MPM Capital in 2003. At Accelerator, he sourced, served on the board of, and led the active day-to-day management of twelve companies. One of those companies, Oncofactor, is based upon technology that Carl invented himself identifying completely novel new targets for cancer. He raised over $40 million for Series A investments in these emerging companies, and helped to raise more than $200 million in follow-on financings in the successful "graduates" of Accelerator. During his tenure at Accelerator, Carl also became a Managing Director at OVP Venture Partners, a successful venture capital firm with more than 25 years investing in Northwestern companies. Carl was a partner in funds VI and VII and led investments in Novomer, Fate Therapeutics, Limerick, and Verdezyne, serving on the boards of Novomer and Fate and as an observer at Limerick and Verdezyne. In addition, as a Managing Director at OVP, Carl led investments in and served on the boards of Accelerator graduates VLST Corp. and Allozyne, Inc. Prior to Accelerator, Carl was a Venture Partner at MPM Capital, in which role he acted as the CEO of Centagenetix, Inc., a company he led into a merger with Elixir Pharmaceuticals in 2003 where he remained on the board until 2005. Prior to MPM Capital, Carl held various roles at Prolinx, Inc., a Bothell, Washington based chemistry tools company.